Fundz Deep Dive
Everything you need to win Evaxion A/S — in one platform.
Who to reach, what to say, and why now on Evaxion A/S — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Evaxion A/S — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Evaxion signs option and license agreement with MSD for vaccine candidate EVX-B3.
Sep 25, 2025•9 months ago
Contract Type
agreement
CopenhagenBiotechnologyHealth CareArtificial IntelligenceresearchDescription
Evaxion A/S has out-licensed its vaccine candidate EVX-B3 to MSD under an agreement that secures an initial payment of $7.5 million. The partnership will allow MSD to manage all further development costs and also entitles Evaxion to future milestone payments and royalties.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months